Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313–7
- 1 June 2023
- journal article
- letter
- Published by Elsevier BV in European Urology
- Vol. 83 (6), e159-e160
- https://doi.org/10.1016/j.eururo.2023.02.029
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder CancerEuropean Urology, 2023
- Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective studyCell Reports Medicine, 2022
- Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular SubtypesEuropean Urology, 2022
- Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerJournal of Clinical Oncology, 2021